Special Issue "Advances in Myocarditis: Molecular and Immune Mechanisms, Diagnosis and Treatment"

Dear Colleagues,

Myocarditis is an inflammatory disease of the heart muscle, both infective and immune in origin. Nowadays, with the advent of endomyocardial biopsy, molecular investigation is also feasible in humans to gain an insight into cell biology and pathogenetic mechanisms for improving diagnosis, therapy and prevention. Moreover, new perspectives are emerging in terms of clinical, non-invasive diagnosis through Cardiac Magnetic Resonance (CMR) and treatment to favor the spontaneous resolution of fulminant myocarditis, by putting the heart temporarily at rest with Extra Corporeal Membrane Oxygenation (ECMO).

Contributions on the following topics are welcome:

• CMR as a novel means of non-invasive clinical diagnosis.
• Molecular diagnosis of viral infections and possible anti-viral therapy.
• ECMO to overcome fulminant-onset myocarditis.
• Advances in therapy for both viral and immune myocarditis.
• The role and types of implantable defibrillator to prevent arrhythmic sudden death.
• The pathogenetic mechanisms of viral myocarditis as a cause of cardiomyocyte death, evolving towards dilated cardiomyopathy.
• The role of endomyocardial biopsy in establishing the histotype of myocarditis, with inherent therapeutic and prognostic implications.
• Vaccinations to prevent viral myocarditis in children.
• COVID myocarditis: immune reaction to vaccination or a settlement of the coronavirus within the myocardium?
• New drug therapy.
• Telling the story of myocarditis, from the invention of the microscope to polymerase chain reaction (PCR).
• Are rheumatic and chagas myocarditis still a big global problem?
• Overall, the role of the immune system in myocarditis.

Dr. Gaetano Thiene
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cardiac magnetic resonance (CMR)
• endomyocardial biopsy
• extra corporeal membrane oxygenation (ECMO)
• immune system
• molecular pathology
• myocarditis
• viruses